Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
May 22, 2026
Why Is Futu Holdings (FUTU) Stock Down -39% Today?

Why Is Futu Holdings (FUTU) Stock Down -39% Today?

Key Takeaways

  • FUTU shares are plunging approximately 39% in Friday premarket trading, last trading near $75.56, down from Thursday's closing price of $123.86
  • The primary catalyst is a formal enforcement action by China's securities regulator, the CSRC, which has filed cases against Futu Securities International (Hong Kong) for operating an unauthorized securities brokerage business targeting mainland Chinese investors without regulatory approval
  • The CSRC — acting jointly with eight other Chinese government agencies — plans to confiscate all illegal gains from Futu's onshore and offshore entities and impose severe additional financial penalties, with no specific dollar amount yet disclosed
  • A two-year mandatory wind-down period has been ordered: existing mainland Chinese clients may only sell positions and withdraw funds; no new buy orders or new inbound fund transfers are permitted
  • Peer stock TIGR (UP Fintech Holding, parent of Tiger Brokers) is similarly implicated in the same enforcement action and also fell sharply in premarket trading
  • Investors are now focused on the formal penalty determination, management's response, and Futu's Q1 2026 earnings report scheduled for May 28, 2026

Opening Summary

Futu Holdings Limited (FUTU) is a Tencent-backed, Hong Kong-headquartered financial technology company operating one of Asia's leading tech-driven online brokerage and wealth management platforms, serving retail and institutional investors primarily across Hong Kong, Singapore, and the broader Chinese diaspora. Shares are tumbling approximately 39% in Friday premarket trade — near $75.56 — after China's securities regulators announced a sweeping multi-agency crackdown against the company for illegally operating a mainland securities brokerage business without official CSRC approval. Thursday's closing price was $123.86. The sell-off is one of the steepest single-session declines in FUTU's history as a U.S.-listed company.

CSRC Enforcement Action: The Core Catalyst

The China Securities Regulatory Commission announced it has formally filed cases and issued prior notices of administrative penalties against onshore and offshore entities of Futu Securities International (Hong Kong), Tiger Brokers (NZ) Limited, and Longbridge Securities (Hong Kong) for operating securities trading marketing, order processing, and related services within mainland China without holding the required CSRC-issued licenses for securities brokerage or margin financing businesses. The CSRC said the illegal activities violated China's Securities Law, Securities Investment Fund Law, and Futures and Derivatives Law, citing Articles 202, 136, and 132 respectively, and characterized the conduct as disrupting market order that "must be resolutely cracked down upon".

Critically, the regulator confirmed it plans to confiscate all illegal gains — derived from both onshore and offshore entities — and impose severe additional monetary penalties. No specific financial amount has been disclosed, leaving the total liability entirely open-ended and injecting a heavy uncertainty premium into FUTU's valuation.

Nine-Agency Coordinated Crackdown

This enforcement action was not taken by the CSRC alone. Eight additional state bodies, including the People's Bank of China, jointly issued an "Implementation Plan for Comprehensive Rectification of Illegal Cross-border Securities, Futures and Fund Management Activities," signaling this is a top-level, systemic policy decision rather than a routine regulatory notice. The plan is explicit: all unauthorized platforms must undergo a two-year rectification period immediately, during which existing mainland Chinese users are restricted to liquidating their holdings and withdrawing funds only, with zero new investment activity permitted.

Once the two-year window expires, affected platforms are required to completely shut down all mainland-facing websites, trading software, and server infrastructure. China's existing legal channels for overseas market access — including Stock Connect, QDII, and the Cross-border Wealth Management Connect program — remain open for domestic investors, and the CSRC confirmed that investor assets on penalized platforms will remain protected during the transition.

Structural Business Risk: Losing the Mainland Market

The operational restrictions imposed represent a severe structural blow to FUTU's growth model. The company has built significant momentum as a gateway for mainland Chinese retail investors seeking access to Hong Kong-listed and U.S.-listed securities, a market that has fueled its rapid user and revenue growth in recent years. The forced exit from that client base — combined with the unknown scale of penalty forfeitures — creates a fundamental earnings power question that markets are now pricing in sharply.

The CSRC's statement made clear that it intends to continue targeting unauthorized overseas brokerages operating domestically: "Going forward, we will continue to crack down on the illegal stockbroking business operated by overseas institutions domestically to fully keep order and maintain the stability of the capital market," it said. This forward-looking language raises the risk that the enforcement climate for offshore brokerages in China will remain severely restrictive beyond the current case.

Historical Context

This is not the first time FUTU has drawn regulatory attention over mainland operations. In December 2022, the CSRC previously identified Futu and UP Fintech as operating illegal cross-border securities activities and banned them from soliciting new mainland clients, which triggered a sharp single-session decline at the time. In May 2023, Futu removed its apps from Chinese app stores in a bid to demonstrate compliance. The May 2026 action is materially more severe — moving from warnings and solicitation bans to formal case filings, asset confiscation proceedings, a multi-agency enforcement plan, and a mandatory wind-down order — a significant escalation in regulatory posture.

Market Context and Trading Activity

Premarket volume in FUTU was dramatically elevated, with over 523,000 shares changing hands before the open, far above typical pre-session levels. Peer stock TIGR suffered comparable losses as UP Fintech's Tiger Brokers unit faces the same CSRC enforcement action. The selloff in both names was sharply divergent from broader U.S. equity futures, reinforcing that this is a company- and sector-specific regulatory shock rather than a macro market move. Chinese fintech and offshore-listed brokerage names broadly came under pressure as investors reassessed the risk profile of any platform with meaningful mainland exposure.

Trending AI Robots

For traders navigating high-volatility sessions like today's, Tickeron's Trending AI Robots page offers a curated view of the platform's best-performing AI trading bots under current market conditions. Tickeron operates hundreds of AI-driven bots covering thousands of tickers, but only those demonstrating the strongest recent performance metrics are featured in the Trending section. Bots vary across strategy type, timeframe, risk profile, and traded symbols — spanning momentum plays, mean-reversion setups, and swing trading across equities and ETFs. Traders seeking systematic, data-driven approaches to volatile markets may find the Trending AI Robots section a valuable starting point for identifying strategies aligned with today's environment.

What Comes Next for FUTU

Futu Holdings is scheduled to report Q1 2026 financial results before U.S. markets open on May 28, 2026, with a management call at 7:30 AM Eastern Time. That report will now serve as a critical platform for management to address the CSRC action directly — including disclosures on the scope of mainland client exposure, any internal assessment of potential penalty size, and an updated strategic roadmap for non-mainland markets such as Singapore, Malaysia, and Australia. The parties have the legal right under Chinese administrative procedure to make statements, present defenses, and formally request hearings before final penalty decisions are issued. Key risks remain: the total financial penalty is unknown, the structural loss of mainland growth optionality is significant, and headline regulatory risk remains elevated. Analysts will closely monitor whether FUTU's international expansion trajectory outside China can credibly absorb the impact of a forced mainland exit.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitation

Related Ticker: FUTU

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


Momentum Indicator for FUTU turns positive, indicating new upward trend

FUTU saw its Momentum Indicator move above the 0 level on July 17, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned positive. In of the 79 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

FUTU moved above its 50-day moving average on July 27, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for FUTU crossed bullishly above the 50-day moving average on July 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FUTU advanced for three days, in of 303 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 193 cases where FUTU Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 49 cases where FUTU's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FUTU declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

FUTU broke above its upper Bollinger Band on July 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.910) is normal, around the industry mean (4.168). P/E Ratio (12.070) is within average values for comparable stocks, (21.675). FUTU's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.669). Dividend Yield (0.024) settles around the average of (0.033) among similar stocks. P/S Ratio (5.043) is also within normal values, averaging (31.028).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. FUTU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FUTU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.

Notable companies

The most notable companies in this group are Morgan Stanley (NYSE:MS), Goldman Sachs Group (NYSE:GS), Charles Schwab Corp (The) (NYSE:SCHW), Gold.com Inc. (NYSE:GOLD).

Industry description

These banks specialize in underwriting (helping companies with debt financing or equity issuances), IPOs, facilitating mergers and other corporate reorganizations and acting as a broker or financial advisor for institutions. They might also trade securities on their own accounts. Investment banks potentially thrive on expanding its network of clients, since that could help them increase profits. Goldman Sachs, Morgan Stanley and CME Group Inc are some of the largest investment banking companies.

Market Cap

The average market capitalization across the Investment Banks/Brokers Industry is 13.05B. The market cap for tickers in the group ranges from 13 to 928.5B. PKRSF holds the highest valuation in this group at 928.5B. The lowest valued company is BFCH at 13.

High and low price notable news

The average weekly price growth across all stocks in the Investment Banks/Brokers Industry was -0%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was -14%. ABTS experienced the highest price growth at 35%, while TOP experienced the biggest fall at -78%.

Volume

The average weekly volume growth across all stocks in the Investment Banks/Brokers Industry was -14%. For the same stocks of the Industry, the average monthly volume growth was -8% and the average quarterly volume growth was -64%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 64
P/E Growth Rating: 70
Price Growth Rating: 62
SMR Rating: 76
Profit Risk Rating: 86
Seasonality Score: -9 (-100 ... +100)
View a ticker or compare two or three
FUTU
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a technology company, which engages in online brokerage services and margin financing services for clients in Hong Kong and China

Industry InvestmentBanksBrokers

Profile
Details
Industry
N/A
Address
95 Queensway
Phone
+852 25233588
Employees
3540
Web
https://www.futuholdings.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.